Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8915 results

  1. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    Awaiting development Reference number: GID-TA11437 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  5. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    Awaiting development Reference number: GID-TA11716 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

    Technology appraisal guidance
    Awaiting development

  7. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    Awaiting development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Apraglutide for treating short bowel syndrome [ID6533]

    Awaiting development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    Awaiting development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    Awaiting development

  12. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  13. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]

    Awaiting development Reference number: GID-TA11085 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development